Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

Bibliographic Details
Main Authors:	C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137920302297

Similar Items

Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era
by: C. Cerchione, et al.
Published: (2020-10-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
by: Anderson, L.D., Jr, et al.
Published: (2022)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-03-01)

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
by: Marina Silvia Parisi, et al.
Published: (2019-10-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS
by: M.E.Z. Capra, et al.
Published: (2020-11-01)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
by: Albert Oriol, et al.
Published: (2021-05-01)

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
by: Evangelos Terpos, et al.
Published: (2021-04-01)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017-08-01)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
by: Mary H. Young, et al.
Published: (2021-08-01)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
by: Teresa Paíno, et al.
Published: (2020-09-01)

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
by: Yu-Chin Hung, et al.
Published: (2021-05-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
by: Terpos E, et al.
Published: (2013-05-01)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
by: Maria Livia Del Giudice, et al.
Published: (2021-08-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
by: Sophia Danhof, et al.
Published: (2015-04-01)

The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01)

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
by: Bai, H., et al.
Published: (2022)

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
by: M. Dimopoulos, et al.
Published: (2020-11-01)

The molecular pathogenesis of multiple myeloma
by: Niccolò Bolli, et al.
Published: (2020-12-01)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
by: Li Y, et al.
Published: (2017-11-01)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
by: Manh-Cuong Vo, et al.
Published: (2018-08-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

Pomalidomide-induced hypothyroidism
by: Sulaiman Haji Ali, et al.
Published: (2017-12-01)

The Role of Pomalidomide-Based Epigenetic Effect on DNMT Genes Expression in Myeloma Cell Line
by: Ali Dehghani Fard, et al.
Published: (2018-06-01)

How I manage frontline transplant-ineligible multiple myeloma
by: Daniele Derudas, et al.
Published: (2020-09-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

How we manage smoldering multiple myeloma
by: Alessandra Romano, et al.
Published: (2020-09-01)

PET/CT in Multiple Myeloma: Beyond FDG
by: Federica Matteucci, et al.
Published: (2021-01-01)

Apatinib as Salvage Therapy for Heavily Pretreated SCLC
by: Fangfang LI, et al.
Published: (2018-07-01)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
by: Massimo Martino, et al.
Published: (2021-05-01)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
by: Li Y, et al.
Published: (2018-05-01)

FDA approves ixazomib in combination with lenalidomide and dexamethasone for multiple myeloma
by: - -
Published: (2015-12-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines
by: Turturro Francesco, et al.
Published: (2011-09-01)